RxDoctor Payments Data

Matthew Fort

Otolaryngology · Birmingham, ALNPI 1760801039

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,858 of the $6,301 with a category attached, or 61.2%. 18 manufacturers reported payments, led by Smith+Nephew at 46.1% of the total. Reporting peaked in 2023 at $3,193 and has fallen 68.1% since, to $1,017 in 2025.

$6,301in general payments, 2019–2025

Across 133 payments — averaging $47.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$3K
  • GSK$517
  • Sanofi$515
  • Regeneron Healthcare Solutions, Inc.$511
  • Inspire Medical Systems, Inc.$402
  • Cochlear Americas$338
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$2,13334%
  • Food & beverage$3,85861%
  • Education$3105%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,301 in reported general payments places this provider in the 85th percentile of 155 otolaryngology providers in Alabama.

See all otolaryngology providers in Alabama

Medicare billing

Part B allowed, 2024
$72,004
Medicare patients
220
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluocinolone Acetonide Oil21$1,615
Ipratropium Bromide50$1,515
Tobramycin-DexamethasoneTobramycin/Dexamethasone23$1,018
Ofloxacin19$851
Montelukast Sodium55$768
Fluticasone Propionate37$758
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav38$647
CefuroximeCefuroxime Axetil18$645
Methylprednisolone29$268
Omeprazole24$176
Mupirocin24$175
Doxycycline Monohydrate14$151
Prednisone44$150
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$124
Ondansetron OdtOndansetron24$117

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →